A share price of Pliant Therapeutics Inc [PLRX] is currently trading at $13.87, down -3.34%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PLRX shares have gain 3.74% over the last week, with a monthly amount glided 31.10%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pliant Therapeutics Inc [NASDAQ: PLRX] stock has seen the most recent analyst activity on December 08, 2023, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $41. Previously, Canaccord Genuity started tracking the stock with Buy rating on May 18, 2023, and set its price target to $48. On April 13, 2023, Robert W. Baird initiated with a Outperform rating and assigned a price target of $44 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $33 on December 14, 2022. JP Morgan initiated its recommendation with a Overweight and recommended $42 as its price target on December 07, 2022. Citigroup started tracking with a Buy rating for this stock on September 01, 2022, and assigned it a price target of $36. In a note dated July 20, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $33 on this stock.
Pliant Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $10.29 and $20.23. Currently, Wall Street analysts expect the stock to reach $40.5 within the next 12 months. Pliant Therapeutics Inc [NASDAQ: PLRX] shares were valued at $13.87 at the most recent close of the market. An investor can expect a potential return of 192.0% based on the average PLRX price forecast.
Analyzing the PLRX fundamentals
Trailing Twelve Months sales for Pliant Therapeutics Inc [NASDAQ:PLRX] were 0.25M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -38.22%, Pretax Profit Margin comes in at -33.56%, and Net Profit Margin reading is -33.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.35 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.55 points at the first support level, and at 13.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.08, and for the 2nd resistance point, it is at 14.30.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pliant Therapeutics Inc [NASDAQ:PLRX] is 16.12. As well, the Quick Ratio is 16.12, while the Cash Ratio is 3.76. Considering the valuation of this stock, the price to sales ratio is 3347.11, the price to book ratio is 1.91.
Transactions by insiders
Recent insider trading involved Coulie Bernard, President and CEO, that happened on Jul 10 ’24 when 38710.0 shares were sold. Chief Medical Officer, Lefebvre Eric completed a deal on Jul 10 ’24 to sell 12319.0 shares. Meanwhile, Chief Financial Officer Cummings Keith Lamont sold 10911.0 shares on Jul 10 ’24.
